Iovance Q4 2024 product revenue $73.7M; FY24 total $164.1M, achieving upper end of guidance

IOVANCE BIOTHERAPEUTICS, INC.

2024-FY EPS reported -$1.28 revenue$164,070,000

Full year 2024 product revenue of $164.1M, within $160-165M guidance; Amtagvi $103.6M, Proleukin $60.5M.
Net loss FY24 $372.2M ($1.28/share) vs $444.0M ($1.89/share) in FY23.
Reaffirms FY25 product revenue guidance of $450-475M; FY25 cash burn expected under $300M.
Cash position ~$422M as of Feb 26, 2025, expected to fund operations into H2 2026.
Dan Kirby named Chief Commercial Officer in Feb 2025; Raj Puri promoted to Chief Regulatory Officer Nov 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.